Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23398466 | 0.85 | ADORA2A (0.41) | ADORA2AADORA2B | |
| SCHEMBL23402396 | 0.82 | CNR1 (0.35) | ADORA2AADORA2B | |
| SCHEMBL23401316 | 0.80 | — | — | |
| SCHEMBL23399969 | 0.79 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL12251595 | 0.79 | ADORA2A (0.39) | ADORA2AADORA2BLMNAALOX15MAPT | |
| SCHEMBL23400263 | 0.78 | — | — | |
| SCHEMBL23402197 | 0.76 | ADORA2A (0.37) | ADORA2AADORA2BLMNAALOX15 | |
| SCHEMBL12732051 | 0.76 | ADORA2A (0.37) | ADORA2AADORA2B | |
| SCHEMBL23399245 | 0.76 | — | — | |
| SCHEMBL23399365 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-20170001996-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001996-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | ADORA2A 3133/4885ADORA2B 3962/4885LMNA 3276/4885 |
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | TH, CYP4X1, CYP4B1 | ADORA2A 2623/4885ADORA2B 2706/4885LMNA 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.